Notably, AR, MYC and E2F1/2 are all established Hsp90 client proteins, and targeting Hsp90 inhibits expression of AR in prostate cancer (reviewed in [41]), and MYC [48,49,50,51] and E2F1 [52,53] in other cancers. This evidence concerns the gene E2F1 and prostate carcinoma.